Silvia Bio, a University of Sheffield spinout, has raised £3 million in Seed funding to help biopharmaceutical companies manufacture complex medicines faster, more reliably, and at lower cost. The round was led by Northern Gritstone and included several venture funds and angel investors. The company is commercializing more than 20 years of biomanufacturing research to address a growing challenge in the production of next-generation therapies.
A Pressing Biomanufacturing Challenge
More than half of new biological medicines are now considered difficult to manufacture because they rely on living mammalian cells that often struggle to produce complex molecules consistently. These challenges create low yields, variable quality, and costly delays for therapies such as antibodies and gene therapies. For biopharmaceutical companies, each day a medicine is delayed can represent around £500,000 in lost sales, while patients wait longer for potentially important treatments.
A Precision Platform for Cell Performance
Silvia Bio addresses this challenge through an integrated platform that identifies the biological bottlenecks limiting cell performance and develops precision media additives to overcome them. Its proprietary cell-profiling technology creates a detailed fingerprint of how cells behave during manufacturing, offering clear and relevant insight into why a process is underperforming. The company then uses these findings to formulate licensable, bioreactor-compatible additives designed to improve product yield and critical quality attributes.
Validation Across Biologics
The platform has already been validated with industrial partners across biologics manufacturing, including antibodies, vaccines, and gene therapies. This validation supports Silvia Bio's plan to develop new licensable products that can be introduced directly into existing manufacturing processes. The company's approach aims to make complex biologics more predictable and economical to produce at scale while maintaining critical quality attributes.
Seed Funding and Investor Support
Northern Gritstone led the Seed round, with additional investment from the Parkwalk Northern Universities Venture Fund, the UK Innovation & Science Seed Fund managed by Future Planet Capital, Wren Capital, and angel investors. The funding will support Silvia Bio as it moves from the University of Sheffield into dedicated laboratory space at the Innovation Centre in Sheffield. It will also enable the company to automate core processes, expand its team, and increase commercial capacity.
Strategic Growth and Commercial Ambitions
Silvia Bio plans to triple its headcount and automate processes that are currently carried out manually. The company will use the new capital to expand its international reach and develop additional licensable products for the biopharmaceutical sector. Its goal is to become a leading global provider of biomanufacturing solutions while supporting partners across antibodies, vaccines, and gene therapies.
Leadership Perspectives on the Funding
Ed Curry, CEO and co-founder, said the platform gives biopharmaceutical companies a clearer view of why cells underperform and provides practical manufacturing solutions. Professor Ashutosh Tiwari of the University of Sheffield described Silvia Bio as an example of the university's innovation ecosystem and its ability to attract investment. Duncan Johnson of Northern Gritstone noted that the company combines scientific insight with a clear commercial proposition to improve yields and reduce delays.
The Seed funding positions Silvia Bio to address a critical bottleneck in next-generation medicine development while supporting a science-led business in the North of England. By helping manufacturers improve yields, reduce delays, and make complex biologics more predictable, the company aims to accelerate patient access to transformative treatments. Its progress reflects the strength of University of Sheffield research and the confidence of investors focused on science and technology startups.